secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001601830-24-000085
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership
--------------------------------------------------------------------------------

- Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.
- REC-3964 (C. diff) Phase 2 start Q4 2024; RBM39 IND Q3 2024; Target Epsilon IND early 2025.
- Bayer first beta-user of LOWE platform; joint oncology project towards Lead Series nomination; 25 data packages Q3 2024.
- ADME industrialization ~90x throughput over manual; genome-scale transcriptomics knockout map; 90% success predicting compound failures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000085/0001601830-24-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000085/rxrx-20240624.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer